Skip to main content
SpringerLink
Log in

Gene Signature of Malignant Pleural Mesothelioma

  • Chapter
  • First Online:
Asbestos and Mesothelioma

Part of the book series: Current Cancer Research ((CUCR))

Abstract

Malignant pleural mesothelioma (MPM) is a rare deadly disease with limited therapeutic options. The application of tailored treatments may increase the efficacy of therapies. The promise of precision medicine is to improve human health by combining biomarkers with clinical data. Therefore, the discovery of gene signatures correlated to clinical characteristics is fundamental to identify patients that can benefit from a specific treatment. Although the “omics”-based analyses have become affordable and enabled a rapid identification of potential biomarkers, the application of gene signatures to personalized clinical decisions in order to improve patient outcome has not been delivered yet. Several attempts have been made using many different technologies such as sequencing, expression, and methylation arrays, and different signatures potentially specific to MPM have been generated. However, the lack of statistical power due to the absence of validation in large cohorts of samples has limited the implementation of these gene signatures in clinical practice. Large-scale validations in prospective cohorts are needed to bring the most promising gene signatures into the clinic.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17:487–500

    Article  CAS  PubMed  Google Scholar 

  • Andrici JA, Sheen L, Sioson K et al (2015) Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol 28:1360–1368

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Battaglia S, Muhitch JB (2016) Unmasking targets of antitumor immunity via high-throughput antigen profiling. Curr Opin Biotechnol 42:92–97

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Bott M, Brevet M, Taylor BS et al (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 43:668–672

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Broadhead ML, Clark JC, Dass CR et al (2010) Microarray: an instrument for cancer surgeons of the future? ANZ J Surg 80:531–536

    Article  PubMed  Google Scholar 

  • Bueno R, Stawiski EW, Goldstein LD et al (2016) Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet 48:407–416

    Article  CAS  PubMed  Google Scholar 

  • Busacca S, Germano S, De Cecco L et al (2010) MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 42:312–319

    Article  CAS  PubMed  Google Scholar 

  • Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin Oncol 29:2–17

    Article  CAS  PubMed  Google Scholar 

  • Chandra V, Kim JJ, Mittal B et al (2016) MicroRNA aberrations: an emerging field for gallbladder cancer management. World J Gastroenterol 22:1787–1799

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chaouche-Mazouni S, Scherpereel A, Zaamoum R et al (2015) Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma. Ann Diagn Pathol 19:193–197

    Article  PubMed  Google Scholar 

  • Cheng W, Ren X, Zhang C et al (2016) Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology 86:2226–2234

    Article  CAS  PubMed  Google Scholar 

  • Chew SH, Toyokuni S (2015) Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic Biol Med 86:166–178

    Article  CAS  PubMed  Google Scholar 

  • Chibon F (2013) Cancer gene expression signatures - the rise and fall? Eur J Cancer 49:2000–2009

    Article  CAS  PubMed  Google Scholar 

  • Christensen BC, Houseman EA, Godleski JJ et al (2009) Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 69(1):227–234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Christensen BC, Houseman EA, Poage GM et al (2010) Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res 70:5686–5694

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Clancy T, Hovig E (2016) Profiling networks of distinct immune-cells in tumors. BMC Bioinformatics 17:263

    Article  PubMed  PubMed Central  Google Scholar 

  • Crovella S, Bianco AM, Vuch J et al (2016) Iron signature in asbestos-induced malignant pleural mesothelioma: a population-based autopsy study. J Toxicol Environ Health A 79:129–141

    Article  CAS  PubMed  Google Scholar 

  • de Reynies A, Jaurand MC, Renier A et al (2014) Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition. Clin Cancer Res 20:1323–1334

    Article  PubMed  Google Scholar 

  • De Rienzo A, Archer MA, Yeap BY et al (2016) Gender-specific molecular and clinical features underlie malignant pleural mesothelioma. Cancer Res 76:319–328

    Google Scholar 

  • De Rienzo A, Cook RW, Wilkinson J, Gustafson CE, Amin W, Johnson CE, Oelschlager KM, Maetzold DJ, Stone JF, Feldman MD, Becich MJ, Yeap BY, Richards WG, Bueno R (2017) Validation of a gene expression test for mesothelioma prognosis in formalin-fixed paraffin-embedded tissues. J Mol Diagn 19:65–71

    Article  PubMed  Google Scholar 

  • De Rienzo A, Dong L, Yeap BY et al (2011) Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 17:310–316

    Article  PubMed  Google Scholar 

  • De Rienzo A, Richards WG, Yeap BY et al (2013) Sequential binary gene ratio tests define a novel molecular diagnostic strategy for malignant pleural mesothelioma. Clin Cancer Res 19:2493–2502

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • De Rienzo A, Yeap BY, Cibas ES et al (2014) Gene expression ratio test distinguishes normal lung from lung tumors in solid tissue and FNA biopsies. J Mol Diagn 16:267–272

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dong L, Bard AJ, Richards WG et al (2009) A gene expression ratio-based diagnostic test for bladder cancer. Adv Appl Bioinforma Chem 2:17–22

    CAS  PubMed Central  Google Scholar 

  • Goossens N, Nakagawa S, Sun X et al (2015) Cancer biomarker discovery and validation. Transl Cancer Res 4:256–269

    CAS  PubMed  PubMed Central  Google Scholar 

  • Gordon GJ (2005) Transcriptional profiling of mesothelioma using microarrays. Lung Cancer 49(Suppl 1):S99–S103

    Article  PubMed  Google Scholar 

  • Gordon GJ, Dong L, Yeap BY et al (2009) Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma. J Natl Cancer Inst 101:678–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Gordon GJ, Jensen RV, Hsiao LL et al (2002) Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62:4963–4967

    CAS  PubMed  Google Scholar 

  • Gordon GJ, Jensen RV, Hsiao LL et al (2003) Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95:598–605

    Article  CAS  PubMed  Google Scholar 

  • Goto Y, Shinjo K, Kondo Y et al (2009) Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 69:9073–9082

    Article  CAS  PubMed  Google Scholar 

  • Greillier L, Baas P, Welch JJ et al (2008) Biomarkers for malignant pleural mesothelioma: current status. Mol Diagn Ther 12:375–390

    Article  CAS  PubMed  Google Scholar 

  • Guo J, Miao Y, Xiao B et al (2009) Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroenterol Hepatol 24:652–657

    Article  CAS  PubMed  Google Scholar 

  • Guo Y, Chen Z, Zhang L et al (2008) Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68(1):26–33

    Article  CAS  PubMed  Google Scholar 

  • Henderson DW, Reid G, Kao SC et al (2013) Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol 66:854–861

    Article  PubMed  Google Scholar 

  • Henley SJ, Larson TC, Wu M et al (2013) Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003–2008. Int J Occup Environ Health 19:1–10

    Article  PubMed  PubMed Central  Google Scholar 

  • Houseman EA, Christensen BC, Karagas MR et al (2009) Copy number variation has little impact on bead-array-based measures of DNA methylation. Bioinformatics 25:1999–2005

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Husain AN, Colby T, Ordonez N et al (2013) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med 137:647–667

    Article  PubMed  Google Scholar 

  • Hwang HC, Sheffield BS, Rodriguez S et al (2016) Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens. Am J Surg Pathol 40:120–126

    Article  PubMed  Google Scholar 

  • Kirschner MB, Cheng YY, Armstrong NJ et al (2015) MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma. Mol Oncol 9:715–726

    Article  CAS  PubMed  Google Scholar 

  • Kirschner MB, Cheng YY, Badrian B et al (2012) Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 7:1184–1191

    Article  CAS  PubMed  Google Scholar 

  • Klutstein M, Nejman D, Greenfield R et al (2016) DNA methylation in cancer and aging. Cancer Res 76:3446–3450

    Article  CAS  PubMed  Google Scholar 

  • Kulis M, Merkel A, Heath S et al (2015) Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nat Genet 47:746–756

    Article  CAS  PubMed  Google Scholar 

  • Lamberti M, Capasso R, Lombardi A et al (2015) Two different serum miRNA signatures correlate with the clinical outcome and histological subtype in pleural malignant mesothelioma patients. PLoS One 10:e0135331

    Article  PubMed  PubMed Central  Google Scholar 

  • Li Y, Li F, Jiang F et al (2016) A mini-review for cancer immunotherapy: molecular understanding of PD-1/PD-L1 pathway & translational blockade of immune checkpoints. Int J Mol Sci 17:1151

    Article  PubMed Central  Google Scholar 

  • Liu G, Cheresh P, Kamp DW (2013) Molecular basis of asbestos-induced lung disease. Annu Rev Pathol 8:161–187

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Maglietta A, Maglietta R, Staiano T et al (2016) The immune landscapes of polypoid and nonpolypoid precancerous colorectal lesions. PLoS One 11:e0159373

    Article  PubMed  PubMed Central  Google Scholar 

  • Micolucci L, Akhtar MM, Olivieri F et al (2016) Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis. Oncotarget 7(36):58606–58637

    PubMed  PubMed Central  Google Scholar 

  • Ohm JE, McGarvey KM, Yu X et al (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237–242

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Panou V, Vyberg M, Weinreich UM et al (2015) The established and future biomarkers of malignant pleural mesothelioma. Cancer Treat Rev 41:486–495

    Article  CAS  PubMed  Google Scholar 

  • Pass HI, Goparaju C, Ivanov S et al (2010) hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 70:1916–1924

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Poste G (2011) Bring on the biomarkers. Nature 469:156–157

    Article  CAS  PubMed  Google Scholar 

  • Reid G (2015) MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets. J Thorac Dis 7:1031–1040

    PubMed  PubMed Central  Google Scholar 

  • Richards WG (2009) Recent advances in mesothelioma staging. Semin Thorac Cardiovasc Surg 21:105–110

    Article  PubMed  Google Scholar 

  • Santarelli L, Strafella E, Staffolani S et al (2011) Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. PLoS One 6:e18232

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Schlesinger Y, Straussman R, Keshet I et al (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39:232–236

    Article  CAS  PubMed  Google Scholar 

  • Sethi S, Ali S, Sethi S et al (2014) MicroRNAs in personalized cancer therapy. Clin Genet 86:68–73

    Article  CAS  PubMed  Google Scholar 

  • Shibata T (2015) Current and future molecular profiling of cancer by next-generation sequencing. Jpn J Clin Oncol 45:895–899

    Article  PubMed  Google Scholar 

  • Shin VY, Chu KM (2014) MiRNA as potential biomarkers and therapeutic targets for gastric cancer. World J Gastroenterol 20:10432–10439

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Testa JR, Cheung M, Pei J et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022–1025

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vandermeers F, Neelature Sriramareddy S, Costa C et al (2013) The role of epigenetics in malignant pleural mesothelioma. Lung Cancer 81:311–318

    Article  PubMed  Google Scholar 

  • Vargas AJ, Harris CC (2016) Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer 16:525–537

    Article  CAS  PubMed  Google Scholar 

  • Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644

    Article  CAS  PubMed  Google Scholar 

  • Walts AE, Hiroshima K, McGregor SM et al (2016) BAP1 immunostain and CDKN2A (p16) FISH analysis: clinical applicability for the diagnosis of malignant mesothelioma in effusions. Diagn Cytopathol 44:599–606

    Article  PubMed  Google Scholar 

  • Weber DG, Johnen G, Bryk O et al (2012) Identification of miRNA-103 in the cellular fraction of human peripheral blood as a potential biomarker for malignant mesothelioma–a pilot study. PLoS One 7:e30221

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Conflict of Interest

Dr. R. Bueno receives funding through Brigham and Women’s Hospital’s International Mesothelioma Program, which receives support from plaintiff law firms. He is also supported by funds from NCI, Verastem, Genentech, Merck, Castle Biosciences, and Roche. The remaining authors have no potential conflicts of interest.

Author information

Authors and Affiliations

  1. The Thoracic Surgery Oncology Laboratory and the International Mesothelioma Program, Division of Thoracic Surgery, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA, 02115, USA

    Assunta De Rienzo, William G. Richards & Raphael Bueno

Authors
  1. Assunta De Rienzo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William G. Richards
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raphael Bueno
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Assunta De Rienzo .

Editor information

Editors and Affiliations

  1. Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA

    Joseph R. Testa

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Cite this chapter

De Rienzo, A., Richards, W.G., Bueno, R. (2017). Gene Signature of Malignant Pleural Mesothelioma. In: Testa, J. (eds) Asbestos and Mesothelioma. Current Cancer Research. Springer, Cham. https://doi.org/10.1007/978-3-319-53560-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-53560-9_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-53558-6

  • Online ISBN: 978-3-319-53560-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation